Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AXS-05 in Major Depressive Disorder
NCT03595579Phase 2Completed
- Sponsor
- Axsome Therapeutics, Inc.
- Start
- May 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dextromethorphan + bupropion in major depressive disorder (MDD), sponsored by Axsome Therapeutics, Inc.. Started May 2018; status: completed.
02
Drugs
dextromethorphan + bupropion
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03595579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03595579.